Mechanism of resistance to proteasome inhibitor bortezomib in multiple myeloma

Multiple myeloma (MM) is a malignant plasma cell disease which occured predominantly in the elderly. In recent years, due to the application of small molecular proteasome inhibitor and immunomodulator, MM has become a chronic disease with good response to new treatments rather than a deadly disease that is lack of effective treatments. However, the occurrence of drug resistance makes MM less likely to be cured, which is one of the biggest challenges in MM clinical treatment. This article will review the mechanisms of acquired resistance to bortezomib in MM, including target genes modification, bypass signaling and so forth. Key words: Multiple myeloma; Drug resistance; Bortezomib; Proteasome inhibitor